4//SEC Filing
Ring Christine 4
Accession 0001817199-26-000002
CIK 0001549595other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 7:57 PM ET
Size
9.0 KB
Accession
0001817199-26-000002
Insider Transaction Report
Form 4
Ring Christine
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-20$1.86/sh+3,760$6,994→ 54,657 total - Sale
Common Stock
[F1][F2]2026-01-20$18.42/sh−3,760$69,273→ 50,897 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F3]2026-01-20−3,760→ 8,643 totalExercise: $1.86Exp: 2029-09-30→ Common Stock (3,760 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring|2026-01-21
Documents
Issuer
Nurix Therapeutics, Inc.
CIK 0001549595
Entity typeother
Related Parties
1- filerCIK 0001817199
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 7:57 PM ET
- Size
- 9.0 KB